KRAS mutations have been reported in 4–22% of LCLC (Rekhtman et al. 2016, Miyoshi et al. 2017), whereas BRAF mutations are rare; 0–3% in LCLC (Miyoshi et al. 2017, George et al. 2018) and 1/110 SCLC-cases (George et al. 2015). Here, KRAS is linked to small cell lung carcinoma.